NAVIDEA BIOPHARMACEUTICALS, INC. Financials Navidea Biopharmaceuticals, Inc.
Equities
NAVB
US63937X2027
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0381 USD | +1.33% |
|
+8.86% | -30.98% |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 58.08 | 18.66 | 22.76 | 57.25 | 30.15 | 6.778 |
| Enterprise Value (EV) 1 | 55.84 | 14.7 | 22.78 | 55.91 | 26.67 | 7.217 |
| P/E ratio | 0.77 x | -1.09 x | -1.66 x | -4.51 x | -2.5 x | -0.38 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 32.1 x | 16 x | 34.6 x | 62.6 x | 56.7 x | 103 x |
| EV / Revenue | 30.8 x | 12.6 x | 34.6 x | 61.1 x | 50.2 x | 110 x |
| EV / EBITDA | -4.29 x | -1.53 x | -2.11 x | -5.25 x | -2.23 x | -0.64 x |
| EV / FCF | -2.87 x | 107 x | -3.39 x | -6.9 x | -7.49 x | -3.16 x |
| FCF Yield | -34.9% | 0.93% | -29.5% | -14.5% | -13.4% | -31.7% |
| Price to Book | 5.11 x | 11.8 x | -15 x | 5.01 x | -283 x | -0.81 x |
| Nbr of stocks (in thousands) | 8,100 | 9,090 | 18,064 | 26,627 | 30,150 | 32,274 |
| Reference price 2 | 7.170 | 2.053 | 1.260 | 2.150 | 1.000 | 0.2100 |
| Announcement Date | 3/15/18 | 3/15/19 | 3/18/20 | 3/26/21 | 3/28/22 | 3/27/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.81 | 1.169 | 0.6578 | 0.915 | 0.5315 | 0.0657 |
| EBITDA 1 | -13 | -9.597 | -10.82 | -10.64 | -11.98 | -11.36 |
| EBIT 1 | -13.26 | -9.747 | -10.96 | -10.71 | -12.06 | -11.45 |
| Operating Margin | -732.37% | -833.57% | -1,666.48% | -1,170.6% | -2,269.07% | -17,441.81% |
| Earnings before Tax (EBT) 1 | -17.79 | -16.17 | -10.94 | -10.72 | -11.71 | -15.18 |
| Net income 1 | 74.95 | -16.11 | -10.95 | -10.72 | -11.73 | -15.18 |
| Net margin | 4,139.67% | -1,378.02% | -1,664.3% | -1,171.75% | -2,207.08% | -23,117.58% |
| EPS 2 | 9.276 | -1.890 | -0.7606 | -0.4765 | -0.3998 | -0.5571 |
| Free Cash Flow 1 | -19.48 | 0.1375 | -6.727 | -8.108 | -3.56 | -2.287 |
| FCF margin | -1,075.96% | 11.75% | -1,022.58% | -886.09% | -669.87% | -3,483.4% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/15/18 | 3/15/19 | 3/18/20 | 3/26/21 | 3/28/22 | 3/27/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 0.02 | - | - | 0.44 |
| Net Cash position 1 | 2.24 | 3.96 | - | 1.33 | 3.48 | - |
| Leverage (Debt/EBITDA) | - | - | -0.002005 x | - | - | -0.0387 x |
| Free Cash Flow 1 | -19.5 | 0.14 | -6.73 | -8.11 | -3.56 | -2.29 |
| ROE (net income / shareholders' equity) | 49.4% | -224% | -1,431% | -1,839% | -878% | 404% |
| ROA (Net income/ Total Assets) | -49.9% | -43.8% | -123% | -112% | -105% | -130% |
| Assets 1 | -150.3 | 36.77 | 8.926 | 9.536 | 11.21 | 11.68 |
| Book Value Per Share 2 | 1.400 | 0.1700 | -0.0800 | 0.4300 | -0 | -0.2600 |
| Cash Flow per Share 2 | 0.3400 | 0.3500 | 0.0500 | 0.1000 | 0.1400 | 0.0600 |
| Capex 1 | 0.03 | 0.05 | - | 0.14 | 0.03 | 0.06 |
| Capex / Sales | 1.86% | 3.95% | - | 14.85% | 4.74% | 96.09% |
| Announcement Date | 3/15/18 | 3/15/19 | 3/18/20 | 3/26/21 | 3/28/22 | 3/27/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -30.98% | 3.81M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- NAVB Stock
- Financials Navidea Biopharmaceuticals, Inc.
